Firm’s CaptureSelect platform will be used.

BAC entered into a collaboration with LFB Biotechnologies to discover and develop a custom CaptureSelect® ligand for the purification of a recombinant Factor VIIa product.

LFB and GTC Biotherapeutics are developing this product. The companies are producing Factor VIIa in the milk of animals that express this recombinant protein during lactation.

“Our technology platform enables us to produce ligands that are not only highly specific for the target protein but will generate a very pure product in a single purification step,” according to Laurens Sierkstra, CEO of BAC.

Previous articleTakeda Signs On as Alnylam’s Asian Partner for $150M Upfront
Next articlePipex Pharmaceuticals Expands Oral Flupirtine License